European Respiratory Journal

Article	Citations
Soteria: deliverance from harm?	1342
The right ventricle tamed	877
Unravelling the “frequent exacerbator” phenotype in cystic fibrosis	238
Chymase-1: a “MAST”-er switch in COPD?	213
If your patient with asthma wheezes when sitting or lying quietly, lung function testing may reveal small airway disease	201
Missing airways, ventilation defects and conductive airway physiology in asthma	187
Epigenome-wide association studies: the exposures of yesterday form the methylations of tomorrow	180
A breath of the future: a novel human model for COPD and beyond	166
The lung that rules the heart	163
Randomised controlled trials utilisingFENOto manage asthma: is it time to acknowledge that “one size does not fit all”?	151
Moving the needle on proteasome inhibitor-induced pulmonary arterial hypertension: a definite maybe	146
Gene–environment interaction at 17q12–q21 locus and its role in asthma pathogenesis	145
Antiviral CD8+T-cell immune responses are impaired by cigarette smoke and in COPD	131
Haemodynamic phenotypes of pulmonary hypertension associated with left heart disease: a moving target	129
Lymphoma in patients with asthma treated with dupilumab: much ado about nothing?	126
Combining rituximab with mycophenolate for the treatment of interstitial lung disease	121
From spatial transcriptomics to mouse model: the (re-)emergence of ductal myofibroblasts as a new cellular target in idiopathic pulmonary fibrosis	117
Novel pathomechanisms of ventilator-induced neonatal lung injury: new targets to overcome ongoing challenges	114
Pleural fluid proteomics from patients with pleural infection shows signatures of diverse neutrophilic responses: The Oxford Pleural Infection Endotyping Study (TORPIDS-2)	113
Shear-wave elastography-guided transthoracic biopsy for lung lesions: a randomized controlled trial	112
Arousal threshold modifies the effect of CPAP on executive function among individuals with obstructive sleep apnoea	110
Idiopathic pleuroparenchymal fibroelastosis: three-dimensional computed tomography assessment of upper-lobe lung volume	108
Collaboration between explainable artificial intelligence and pulmonologists improves the accuracy of pulmonary function test interpretation	107
Plasma cells: a feasible therapeutic target in pulmonary fibrosis?	105
Fibroblast heterogeneity in pulmonary fibrosis: a new target for therapeutics development?	102

Repositioning of ezetimibe for the treatment of idiopathic pulmonary fibrosis	97
Extensive acute and sustained changes to neutrophil proteomes post-SARS-CoV-2 infection	96
Natural decline in pulmonary function following bilateral lung transplantation: a single-centre study	96
Salivary polyreactive antibodies andHaemophilus influenzaeare associated with respiratory infection severity in young children with recurrent respiratory infections	91
A normal BNP does not reliably exclude pulmonary hypertension in interstitial lung disease	84
Prenatal exposure to greenness and early childhood pneumonia: a nationwide study in Japan	83
Epidemiological cut-off values for a 96-well broth microdilution plate for high-throughput research antibiotic susceptibility testing of M. tuberculosis	81
Long-term radiological and pulmonary function abnormalities at 3 years after COVID-19 hospitalisation: a longitudinal cohort study	80
Revisiting asthma pharmacotherapy: where do we stand and where do we want to go?	80
Treatment algorithm for pulmonary arterial hypertension	79
RIPK1 kinase-dependent inflammation and cell death contribute to the pathogenesis of COPD	77
Tricuspid regurgitation in pulmonary arterial hypertension: a right ventricular volumetric and functional analysis	77
Pirfenidone in post-COVID-19 pulmonary fibrosis (FIBRO-COVID): a phase 2 randomised clinical trial	76
Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long-COVID symptoms	75
Invisibility of breathlessness in clinical consultations: a cross-sectional, national online survey	74
A patient-tailored approach for corticosteroid treatment in COVID-19: still not there yet	72
Cystic fibrosis macrophage function and clinical outcomes after elexacaftor/tezacaftor/ivacaftor	72
Genomic classifier for usual interstitial pneumonia combined with bronchoalveolar lavage cellular profile: potential use in the clinical management of new onset ILD?	71
Lunsekimig's bispecific targeting of IL-13 and TSLP in asthma: dual targets for synergistic effects?	70
Real-world monitoring of elexacaftor/tezacaftor/ivacaftor trough concentrations in adults with cystic fibrosis	69
Risk of rifampicin resistance emergence after incomplete first-line tuberculosis treatment	65
The impact of oral anticoagulants on idiopathic pulmonary fibrosis risk and prognosis: a population study	65
Challenges in harmonising terms and patterns among interstitial pneumonias: enter idiopathic bronchiolocentric interstitial pneumonia	65
No exposure left behind: time to pay attention to children's chemical environment in lung development	65
Trends in COVID-19-associated mortality in patients with pulmonary hypertension: a COMPERA analysis	64
Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme	64
The association of eicosanoids and eicosanoid-related metabolites with pulmonary hypertension	64
Inhaled seralutinib exhibits potent efficacy in models of pulmonary arterial hypertension	61
The association between immunosuppressants and outcomes of COVID-19	60
Particulate matter-related ITIH4 deficiency is associated with an emphysema phenotype of COPD through JNK-dependent and JNK-independent signalling	60
Associations of hiatus hernia with CT-based interstitial lung changes: the MESA Lung Study	59
The limits of normal of pulmonary arterial wedge pressure	59
Small packages but big insights: extracellular vesicles as biomarkers in interstitial lung disease associated with systemic sclerosis	59
Are intravenous corticosteroid pulses superior to low dose corticosteroids in patients with severe COVID-19?	57
Reply: Tuberculosis screening in migrants to the EU/EEA and UK	57
Pleural mesothelioma: surgery questioned again?	56
Selexipag for inoperable CTEPH: why meeting a primary endpoint simply isn't enough	56
List ofEuropean Respiratory Journalpeer reviewers 2023	55
Response from the authors: As-needed ICS/formoterol or as-needed SABA in mild asthma?	55
“Age-related changes in plasma biomarkers and their association with mortality in COVID-19.” E.H.A. Michels, B. Appelman, J. de Brabander,et al.Eur Respir J2023; 62: 2300011.	54
Single-inhaler tripleversusdual bronchodilator therapy for GOLD group E and other exacerbating patients with COPD: real-world comparative effectiveness and safety	53
FEV1Q: what (even) is normal lung function?	53
Clinical, physiologic, imaging, and molecular responses to cannabis smoking: the Canadian Users of Cannabis Smoke (CANUCK) Study	51
Leukocytic ADAM10 and ADAM17 modulate disease severity and systemic outcome in bacterial and viral pneumonia	51
CPAP recall and cancer risk: should we be concerned?	50
The risk of hypoventilation during bronchoscopy under oxygen and procedural sedation	50
Cystic fibrosis in Europe: improved lung function and longevity – reasons for cautious optimism, but challenges remain	49
Pulmonary hypertension in patients with Noonan syndrome	49
WHO online guide on the use of digital technologies for tuberculosis programmes	49
Immunogenicity and safety of coadministration of COVID-19 and influenza vaccination	47

Inhaled recombinant GM-CSF reduces the need for whole lung lavage and improves gas exchange in autoimmune pulmonary alveolar proteinosis patients	47
Theratyping in cystic fibrosis: filling the knowledge gaps	47
Sputum metagenomics in bronchiectasis reveals pan-European variation: an EMBARC-BRIDGE study	47
Early-life exposure to a mixture of phenols and respiratory health in preschool children	46
Small extracellular vesicles and induction of epithelial-to-mesenchymal transition in lymphangioleiomyomatosis	46
Reply to: Cause or consequence?	46
Muscle sympathetic nerve activity and adaptive servo-ventilation: questions remain	45
An attack of asthma is not an attack of the heart: clarifying causal links between asthma and incident coronary heart disease	45
Vocal cord paralysis as a rare complication of bronchoscopic lung volume reduction: a case series of five patients	45
Comment on: Combination therapy with long-acting bronchodilators and the risk of major adverse cardiovascular events in patients with COPD: a systematic review and meta-analysis	45
Cardiopulmonary response to exercise in adults born very preterm	45
Oral corticosteroids in asthma and beyond: moving forward	44
Treat-and-repair: a simple but powerful term for a complex multimodal approach in patients with pulmonary arterial hypertension associated with congenital heart disease	44
Liver cancer in severe alpha-1 antitrypsin deficiency: who is at risk?	43
COVID-19 changed the world – without changing CTEPH	42
ERJPodcast January 2024: The microbiome in early life and childhood asthma	42
Multitasking within the airway epithelium	42
Filters used for pulmonary function testing	41
Contributions to simplifying the global interpretation of spirometry: high quality spirometry data from Asia	41
Metabolomics in pulmonary medicine: extracting the most from your data	40
“Lung function trajectories in South African children with pulmonary tuberculosis compared to those with non-TB lower respiratory tract infection: a prospective study.” D.M. Gray, L. Githinji, K. Brit	40
Unbowed, unbent, unbroken: predicting pulmonary hypertension using echocardiography	40
The proteomic landscape of blood monocytes in community-acquired pneumonia	40
ERJ Podcast October 2023: ERS short guidelines for the use of as-needed ICS/formoterol in mild asthma	40
Respective roles of non-pharmaceutical interventions in bronchiolitis outbreaks: an interrupted time-series analysis based on a multinational surveillance system	40
Heart rate response and cardiovascular risk during obstructive sleep apnoea: an easy biomarker derived from pulse oximetry	40
Transcriptomic clustering of critically ill COVID-19 patients	39
Risk assessment of systemic sclerosis-associated pulmonary arterial hypertension: cardiac indexversusstroke volume index	39
Bronchoconstriction with inhaled ATP in healthy volunteers	39
Right ventricular–pulmonary arterial coupling and its relationship to exercise haemodynamics in a continuum of patients with pulmonary vascular disease due to chronic thromboembolism	39
Treatment outcomes of multidrug-resistant tuberculosis with chronic kidney/liver disease	39
Reply: The new ERS/ATS standards on lung function test interpretation: some extant limitations	39
Prolonged higher dose methylprednisoloneversusconventional dexamethasone in COVID-19 pneumonia: a randomised controlled trial (MEDEAS)	38
Epigenetic age among US adults with chronic respiratory diseases: results from NHANES 1999–2002	38
Skewed adaptive immune responses are involved in alpha-1 antitrypsin deficiency emphysema	37
Flavonoid intakes inversely associate with COPD in smokers	37
MK-5475, an inhaled soluble guanylate cyclase stimulator, for treatment of pulmonary arterial hypertension: the INSIGNIA-PAH study	37
Indoor microbiome, microbial and plant metabolites, chemical compounds, and asthma symptoms in junior high school students: a multicentre association study in Malaysia	37
Moving the dial on identifying endotypes of asthma from early life	36
European Respiratory Society guidelines on transbronchial lung cryobiopsy in the diagnosis of interstitial lung diseases	36
European Respiratory Society guidelines for the diagnosis of asthma in adults	36
Impact of the expanded label for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del variant in the USA	36
Air pollution and COPD: GOLD 2023 committee report	36
Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension	36
What can lockdowns tell us about the underlying causes of asthma exacerbations? A retrospective cohort study	35
Peripheral pulmonary artery stenosis in adults: a novel type of pulmonary vascular disease with a strong genetic background	35
Presenting clinical data for the hazard classification of chemical respiratory sensitisers	35
Reply to: Pirfenidone and lung cancer in idiopathic pulmonary fibrosis: mind the index date, detection bias and competing risks	35
Spirometry forced expiratory time is driven by airflow limitation in asthmatic children	35
ERJPodcast January 2025: Treatment response to mepolizumab in severe eosinophilic asthma	35
Reducing the pressure in pulmonary arterial hypertension: sotatercept, haemodynamics and the right ventricle	34
Inhaled treprostinil for interstitial lung disease-associated pulmonary hypertension: a silver lining on a very dark cloud	34
I love you with all my lungs: a viewpoint on communicating effectively and positively about lung health	34
Tracing the origins of fibrotic fibroblasts: does the name matter? Look at the genes!	34
Interalveolar pore morphology in (pre-)COPD stages and associations with small airways	34
Primary spontaneous pneumothorax: does size matter?	33
Airflow-based prediction of lateral wall collapse: advancing personalised hypoglossal nerve stimulation in obstructive sleep apnoea	33
Lung structure and longitudinal change in cardiac structure and function: the MESA COPD Study	33
Aspergillussensitisation: an underappreciated treatable trait in airway disease	33
Decoding the eosinophil connection: implications for precision treatment of emphysematous in COPD	33
Antigen identification and avoidance on outcomes in fibrotic hypersensitivity pneumonitis	33
Nasal airway microRNA profiling of infants with severe bronchiolitis and risk of childhood asthma: a multicentre prospective study	33
The COVID-19 pandemic and pulmonary arterial hypertension in Italy: adaptation, outcomes and valuable lessons learned	33
Respiratory support and bronchopulmonary dysplasia in infants born at 22–26 weeks gestation in Sweden, 2004–2007 and 2014–2016	32
Incidence of interstitial lung abnormalities: the MESA Lung Study	32
Combining digital adherence technology and therapeutic drug monitoring for personalised tuberculosis care	32
Relieving dyspnoea through the brain	32
A range of 30–62% of functioning multiciliated airway cells is sufficient to maintain ciliary airway clearance	32
The longitudinal microbial and metabolic landscape of infant cystic fibrosis: the gut–lung axis	32
The role of precision medicine in interstitial lung disease	32
Developing, validating, updating and judging the impact of prognostic models for respiratory diseases	31
Now we know: chronic exposure to air pollutants is a risk factor for the development of idiopathic pulmonary fibrosis	31
Leukotriene receptor antagonists and risk of neuropsychiatric events in children, adolescents and young adults: a self-controlled case series	31
Technical standards for respiratory oscillometry and bronchodilator response cut-offs	31
Health effects of exposure to residential air pollution in patients with pulmonary arterial hypertension: a cohort study in Belgium	31
Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studi	31
Lung function during and after acute respiratory infection in COVID-19 positive and negative outpatients	31
Quantifying COPD as a risk factor for cardiac disease in a primary prevention cohort	31
Impact of elexacaftor/tezacaftor/ivacaftor therapy on lung clearance index and magnetic resonance imaging in children with cystic fibrosis and one or twoF508delalleles	31
Dyspnoea in acutely ill mechanically ventilated adult patients: an ERS/ESICM statement	31

Up-regulated matrix metalloproteinase activity in soil-transmitted helminth–tuberculosis co-infection is associated with increased lung pathology	30
Dupilumab efficacy and safety in patients with asthma and blood eosinophils ≥500 cells·µL−1	30
How bad is your cough? The McMaster Cough Severity Questionnaire as a new tool to measure chronic cough	30
Pulmonary hypertension associated with left heart disease	30
Dexamethasone for preterm infants at risk of bronchopulmonary dysplasia: is timing everything?	30
Pathogenic variants inCFAP46,CFAP54,CFAP74andCFAP221cause primary ciliary dyskinesia with a defective C1d projection of the central apparatus	30
Reply: Cognitive behavioural therapy sessions approach ineffective for anxiety and depression in COPD: is the door closed for good?	29
All roads lead to COPD… or not?	28
ERJPodcast July 2023: The HISTORIC study	28
NSAID-exacerbated respiratory disease, dupilumab and aspirin tolerance	28
Opioids for dyspnoea in interstitial lung disease: does the sequence and timing of therapy matter?	28
ERJPodcast December 2023: Year in review	28
Predicting asthma exacerbations: is there utility in noninvasive assessment of distal airway inflammation using multiple flowFENO?	28
List ofEuropean Respiratory Journalpeer reviewers 2022	28
The identification of prevalent tuberculosis disease through infection screening among high-risk migrants in the Netherlands	28
Ensuring availability of respiratory medicines in times of European drug shortages	28
“From pre-COPD to COPD: a Simple, Low cost and easy to IMplement (SLIM) risk calculator.” M.J. Divo, C. Liu, F. Polverino,et al.Eur Respir J2023; 62: 2300806.	28
The evidence base for ICS/formoterol maintenance and reliever therapy in severe asthma	28
Nebulised liposomal amphotericin-B: a promising strategy for preventing ABPA relapse	28
Neutrophil elastase-dependent cleavage of LTA4H alters its aminopeptidase activity in cystic fibrosis	27
Whole lung directed anti-muscarinic therapy improves small airway dysfunction in COPD patients	27
Decoding the complexity: mechanistic insights into comorbidities in idiopathic pulmonary fibrosis	27
Tofacitinib in anti-MDA5-positive dermatomyositis-associated interstitial lung disease: a new standard of care emerges	27
A European multi-center, randomized controlled trial of Pirfenidone in bronchiolitis obliterans syndrome after bilateral lung transplantation	27
Extracorporeal photopheresis for the prevention of rejection after lung transplantation: a prospective randomised controlled trial	27
De novo SRRM2 variants in neuroendocrine cell hyperplasia of infancy and persistent tachypnea of infancy	27
Multi-beat pressure volume loop-derived right ventricular-pulmonary arterial coupling predicts transplant-free survival in pulmonary arterial hypertension	27
Intravenous methylprednisolone pulses in hospitalised patients with severe COVID-19 pneumonia: a double-blind, randomised, placebo-controlled trial	27
Genetic associations between serotonin receptor 1F (HTR1F) regulatory variation and sleep apnoea in non-obese individuals: insights from GWAS and eQTL analyses	27
Extracorporeal life support as a bridge to lung transplantation strategy in anti-MDA5+ rapidly progressive interstitial lung disease is life-saving but with persistent difficulties at the bedside	27
“Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension.” Mark Toshner, Colin Church, Lars Harbaum,et al.Eur Respir	27
Reply: SABRE for airway quantification in idiopathic pulmonary fibrosis: clarifications, limitations, and next steps	26
ERS technical standards for using type III devices (limited channel studies) in the diagnosis of sleep disordered breathing in adults and children	26
Management of pulmonary hypertension in special conditions	26
Development and validation of a predictive 6-min walk score in patients with idiopathic pulmonary fibrosis	26
Pirfenidone and risk of lung cancer development in idiopathic pulmonary fibrosis: a nationwide population-based study	26
Pulse oximeter measurements vary across ethnic groups: an observational study in patients with COVID-19	26
Phenotyping the responses to systemic corticosteroids in the management of asthma attacks (PRISMA)	25
Low smoking exposure and development and prognosis of COPD over four decades: a population-based cohort study	25
Uptake and 4-week quit rates from an opt-out co-located smoking cessation service delivered alongside community-based low-dose computed tomography screening within the Yorkshire Lung Screening Trial	25
Progressive pulmonary fibrosis: an expert group consensus statement	25
Integrating hot topics and implementation of treatable traits in asthma	25
Clinical trial design, end-points, and emerging therapies in pulmonary arterial hypertension	25
An electrocardiogram-based AI algorithm for early detection of pulmonary hypertension	25
Eligibility criteria from pharmaceutical randomised controlled trials of idiopathic pulmonary fibrosis: a registry-based study	25
Gut microbiota-derived succinate aggravates acute lung injury after intestinal ischaemia/reperfusion in mice	25
ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia	25
Uncovering early COPD? The T-slope as a novel CT biomarker for evaluating airway narrowing	24
Cancer risk associated with alpha-1-antitrypsin deficiency: only large registries will give us the answer	24
Heart or lungs? Why not both!	24
“Interstitial lung abnormalities are associated with decreased mean telomere length.” R.K. Putman, G.T. Axelsson, S.Y. Ash,et al.Eur Respir J2022; 60: 2101814	24
Comment on: Inflammatory plasma protein levels are elevated years before sarcoidosis diagnosis: a nested case–control study in Sweden	24
The rat takes the cheese: a novel model of CFTR-dependent chronic bacterial airway infection	24
“Post tuberculosis”: the urgent need for inclusion of lung health outcomes in tuberculosis treatment trials	24
Reply to: Risk factors for disease progression in fibrotic hypersensitivity pneumonitis	24
Latent COPD: a proposed new term in the disease nomenclature	24
The interface in home non-invasive ventilation: is the nasal mask better?	24
Drug-induced lung disease: unwanted collateral damage	23
TB or not TB: does AI have an answer for children?	23
MRI pulmonary artery flow detects lung vascular pathology in preterms with lung disease	23
Reversible carfilzomib-induced pulmonary arterial hypertension: don't take your eyes off the ball!	23
Building translational bridges in idiopathic pulmonary fibrosis research: from epithelial dysfunction to dysregulated macrophage polarisation and fibrogenesis	23
“Spatial transcriptomics for respiratory research and medicine.” S. Curras-Alonso, J. Soulier, T. Walter, et al. Eur Respir J 2021; 58: 2004314	23
The ERS PROFILE.net Clinical Research Collaboration is dedicated to the set-up of an academic network to enhance imaging-based management of progressive pulmonary fibrosis	23
Right heart function during and after pregnancy in women with pulmonary arterial hypertension	23
Reply to: Insights on the ERS/ESTS statement on the management of pleural infection in adults	23
Vulnerability to acid reflux of the airway epithelium in severe asthma	23
Increasing physical activity in severe asthma: a systematic review and meta-analysis	22
AMR-Lung: a European Clinical Research Collaboration on antimicrobial resistance in chronic lung disease	22
How do people with COPD walk? A European study on digitally measured real-world gait	22
Artificial Intelligence in Idiopathic Pulmonary Fibrosis: Advances, Challenges, and Future Directions	22
Deep phenotyping of unaffected carriers of pathogenicBMPR2variants screened for pulmonary arterial hypertension	22
Mycobacterium aviumcomplex genomics and transmission in a London hospital	22
Genome-wide association study of susceptibility toPseudomonas aeruginosainfection in cystic fibrosis	22
Saline at lower tonicity in cystic fibrosis (SALTI-CF) trial comparing 0.9%versus3%versus6% nebulised saline	22
CPAP resumption after a first termination and impact on all-cause mortality in France	22
Sequential multimodal therapy in chronic thromboembolic pulmonary hypertension with mixed anatomical lesions: a proof of concept	21
Inhaled corticosteroids for outpatients with COVID-19: a meta-analysis	21
The paradox of the safer cigarette: understanding the pulmonary effects of electronic cigarettes	21
Associations of combined phenotypic ageing and genetic risk with incidence of chronic respiratory diseases in the UK Biobank: a prospective cohort study	20
The causal relationship between gastro-oesophageal reflux disease and idiopathic pulmonary fibrosis: a bidirectional two-sample Mendelian randomisation study	20
European Respiratory Society clinical practice guideline for the management of adult bronchiectasis	20
Endothelial cells in pulmonary fibrosis: more than a bystander	20
Sfrp1 inhibits lung fibroblast invasion during transition to injury-induced myofibroblasts	20
Tailored psychological intervention for anxiety or depression in COPD (TANDEM): a randomised controlled trial	20
Characteristics and outcomes of patients developing pulmonary hypertension associated with proteasome inhibitors	20
European Respiratory Society guidelines for the diagnosis and management of pulmonary alveolar proteinosis	20
Treatable traits: a comprehensive precision medicine approach in interstitial lung disease, but why were acute exacerbations not considered?	19
From small to big, using microRNA profiling to investigate infant origins of childhood asthma	19
Reply to: The puzzles surrounding the impact of face masks on 6-minute walking distance in pulmonary hypertension	19
Sorting the wheat from the chaff: the innovative case of precision transpulmonary metabolomics	19
Clarification of author disclosures for fourERJarticles	19
Lung cancer in pulmonary fibrosis: no room for nihilism!	19
Overweight and dysanapsis in childhood asthma	19
Bronchiectasis in low- and middle-income countries: the importance of the wider view	19